RS63836B1 - Products and compositions - Google Patents
Products and compositionsInfo
- Publication number
- RS63836B1 RS63836B1 RS20221162A RSP20221162A RS63836B1 RS 63836 B1 RS63836 B1 RS 63836B1 RS 20221162 A RS20221162 A RS 20221162A RS P20221162 A RSP20221162 A RS P20221162A RS 63836 B1 RS63836 B1 RS 63836B1
- Authority
- RS
- Serbia
- Prior art keywords
- compositions
- products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17165129 | 2017-04-05 | ||
GBGB1707203.4A GB201707203D0 (en) | 2017-05-05 | 2017-05-05 | Modified positions |
GBGB1708397.3A GB201708397D0 (en) | 2017-05-25 | 2017-05-25 | Modified positions |
EP17201352 | 2017-11-13 | ||
PCT/EP2018/058766 WO2018185241A1 (en) | 2017-04-05 | 2018-04-05 | Products and compositions |
EP18715706.0A EP3607069B1 (en) | 2017-04-05 | 2018-04-05 | Products and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
RS63836B1 true RS63836B1 (en) | 2023-01-31 |
Family
ID=61899311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20221162A RS63836B1 (en) | 2017-04-05 | 2018-04-05 | Products and compositions |
Country Status (17)
Country | Link |
---|---|
US (2) | US11015198B2 (en) |
EP (2) | EP3607069B1 (en) |
JP (2) | JP7155239B2 (en) |
CN (1) | CN110520531A (en) |
AU (1) | AU2018247925B2 (en) |
CA (1) | CA3057565A1 (en) |
DK (1) | DK3607069T3 (en) |
ES (1) | ES2932831T3 (en) |
FI (1) | FI3607069T3 (en) |
HR (1) | HRP20221400T1 (en) |
HU (1) | HUE061247T2 (en) |
IL (1) | IL268828A (en) |
LT (1) | LT3607069T (en) |
PL (1) | PL3607069T3 (en) |
RS (1) | RS63836B1 (en) |
SI (1) | SI3607069T1 (en) |
WO (1) | WO2018185241A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
US11753638B2 (en) | 2016-08-12 | 2023-09-12 | University Of Massachusetts | Conjugated oligonucleotides |
IL269517B1 (en) | 2017-04-05 | 2024-09-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of a target gene in a cell, conjugates thereof, compositions comprising them, and therapeutic uses thereof |
US11015198B2 (en) | 2017-04-05 | 2021-05-25 | Silence Therapeutics Gmbh | Products and compositions |
EP3483269A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
WO2018237245A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | Two-tailed self-delivering sirna and related methods |
KR102553382B1 (en) | 2017-11-13 | 2023-07-07 | 사일런스 테라퓨틱스 게엠베하 | Nucleic acids for inhibiting the expression of LPA in cells |
AU2018374219C1 (en) | 2017-12-01 | 2023-05-11 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
US11661603B2 (en) | 2018-01-16 | 2023-05-30 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting ALDH2 expression |
EP3598995A1 (en) * | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Products and compositions |
WO2020041769A1 (en) * | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
PL3880818T3 (en) | 2018-11-13 | 2023-01-23 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
KR20210116509A (en) * | 2019-01-16 | 2021-09-27 | 젠자임 코포레이션 | SERPINC1 IRNA composition and method of use thereof |
EP3947683A1 (en) * | 2019-04-04 | 2022-02-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
WO2021030213A1 (en) | 2019-08-09 | 2021-02-18 | University Of Massachusetts | Chemically modified oligonucleotides targeting snps |
US20210115442A1 (en) * | 2019-08-23 | 2021-04-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
CA3170466A1 (en) | 2020-03-06 | 2021-09-10 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
EP4213882A1 (en) | 2020-09-15 | 2023-07-26 | Verve Therapeutics, Inc. | Lipid formulations for gene editing |
EP4240851A1 (en) | 2020-11-04 | 2023-09-13 | Universität Bern | Nucleic acids for inhibiting expression of pros1 in a cell |
WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
AR126207A1 (en) | 2021-06-23 | 2023-09-27 | Univ Massachusetts | ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS OPTIMIZED FOR THE TREATMENT OF PRE-ECLAMPIA AND OTHER ANGIOGENIC DISORDERS |
US11879125B2 (en) | 2022-03-16 | 2024-01-23 | Empirico Inc. | GalNAc compositions for improving siRNA bioavailability |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9201440A (en) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennary cluster glycosides, their preparation and application. |
US7667030B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
CA2619876A1 (en) | 2005-08-17 | 2007-02-22 | Sirna Therapeutics, Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
US20090306178A1 (en) * | 2006-03-27 | 2009-12-10 | Balkrishen Bhat | Conjugated double strand compositions for use in gene modulation |
WO2009002944A1 (en) | 2007-06-22 | 2008-12-31 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
AU2008333811B2 (en) | 2007-12-04 | 2014-05-01 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
AU2009241591A1 (en) | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Optimized methods for delivery of DSRNA targeting the PCSK9 gene |
WO2009102427A2 (en) | 2008-02-11 | 2009-08-20 | Rxi Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
EP2342616A2 (en) | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
AU2011302152B2 (en) | 2010-09-15 | 2015-06-11 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
WO2012094115A1 (en) | 2010-12-17 | 2012-07-12 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of flt3 genes |
US9322020B2 (en) * | 2011-06-06 | 2016-04-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of isocitrate dehydrogenase (IDH1) gene expression |
CN106434665B (en) | 2011-06-30 | 2021-06-08 | 箭头药业股份有限公司 | Compositions and methods for inhibiting gene expression of hepatitis b virus |
KR102263352B1 (en) | 2011-11-18 | 2021-06-11 | 알닐람 파마슈티칼스 인코포레이티드 | RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES |
EA201490993A1 (en) | 2011-11-18 | 2014-09-30 | Элнилэм Фармасьютикалз, Инк. | MODIFIED MEANS OF RNA |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
CN108220295B (en) | 2012-12-05 | 2022-09-02 | 阿尔尼拉姆医药品有限公司 | PCSK9 iRNA compositions and methods of use thereof |
KR20160002977A (en) | 2013-05-01 | 2016-01-08 | 아이시스 파마수티컬즈 인코포레이티드 | Compositions and methods |
CA2917161C (en) | 2013-07-11 | 2023-12-12 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
WO2015188194A1 (en) | 2014-06-06 | 2015-12-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
KR102630289B1 (en) | 2014-08-20 | 2024-01-31 | 알닐람 파마슈티칼스 인코포레이티드 | Modified double-stranded rna agents |
WO2016085852A1 (en) * | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
CN108064313B (en) | 2015-03-17 | 2021-07-30 | 箭头药业股份有限公司 | Compositions and methods for inhibiting gene expression of factor XII |
US20160272970A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
SI3277814T1 (en) * | 2015-04-03 | 2020-12-31 | University Of Massachusetts | Oligonucleotide compounds for targeting huntingtin mrna |
US20160319278A1 (en) * | 2015-04-03 | 2016-11-03 | University Of Massachusetts | Fully stabilized asymmetric sirna |
JP7336191B2 (en) | 2015-08-07 | 2023-08-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | RNAi therapy for hepatitis B virus infection |
WO2017030973A1 (en) * | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
JOP20210043A1 (en) | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | Compositions and Methods for Inhibiting Gene Expression of LPA |
EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
CN114736256A (en) | 2016-06-06 | 2022-07-12 | 箭头药业股份有限公司 | 5' -cyclic phosphonate modified nucleotide |
JOP20170161A1 (en) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | RNAi Agents for Hepatitis B Virus Infection |
CN110268060B (en) | 2017-01-10 | 2024-07-26 | 箭头药业股份有限公司 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions comprising AAT RNAi agents, and methods of use |
JP2020505415A (en) | 2017-01-30 | 2020-02-20 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Compositions and methods for inhibiting factor XII gene expression |
US11015198B2 (en) | 2017-04-05 | 2021-05-25 | Silence Therapeutics Gmbh | Products and compositions |
JP7247167B2 (en) * | 2017-04-05 | 2023-03-28 | サイレンス・セラピューティクス・ゲーエムベーハー | Products and compositions |
PE20201283A1 (en) | 2017-09-11 | 2020-11-24 | Arrowhead Pharmaceuticals Inc | IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) |
JOP20200050A1 (en) | 2017-09-14 | 2020-03-05 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use |
KR102553382B1 (en) * | 2017-11-13 | 2023-07-07 | 사일런스 테라퓨틱스 게엠베하 | Nucleic acids for inhibiting the expression of LPA in cells |
AU2018374219C1 (en) | 2017-12-01 | 2023-05-11 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
PL3880818T3 (en) * | 2018-11-13 | 2023-01-23 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
-
2018
- 2018-04-05 US US16/497,000 patent/US11015198B2/en active Active
- 2018-04-05 SI SI201830836T patent/SI3607069T1/en unknown
- 2018-04-05 WO PCT/EP2018/058766 patent/WO2018185241A1/en unknown
- 2018-04-05 LT LTEPPCT/EP2018/058766T patent/LT3607069T/en unknown
- 2018-04-05 EP EP18715706.0A patent/EP3607069B1/en active Active
- 2018-04-05 JP JP2020504436A patent/JP7155239B2/en active Active
- 2018-04-05 DK DK18715706.0T patent/DK3607069T3/en active
- 2018-04-05 HR HRP20221400TT patent/HRP20221400T1/en unknown
- 2018-04-05 RS RS20221162A patent/RS63836B1/en unknown
- 2018-04-05 FI FIEP18715706.0T patent/FI3607069T3/en active
- 2018-04-05 HU HUE18715706A patent/HUE061247T2/en unknown
- 2018-04-05 EP EP22202294.9A patent/EP4219713A3/en active Pending
- 2018-04-05 ES ES18715706T patent/ES2932831T3/en active Active
- 2018-04-05 PL PL18715706.0T patent/PL3607069T3/en unknown
- 2018-04-05 CA CA3057565A patent/CA3057565A1/en active Pending
- 2018-04-05 AU AU2018247925A patent/AU2018247925B2/en active Active
- 2018-04-05 CN CN201880021538.7A patent/CN110520531A/en active Pending
-
2019
- 2019-08-21 IL IL26882819A patent/IL268828A/en unknown
-
2021
- 2021-03-31 US US17/219,265 patent/US12084656B2/en active Active
-
2022
- 2022-10-04 JP JP2022160357A patent/JP2022173554A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220090067A1 (en) | 2022-03-24 |
EP3607069B1 (en) | 2022-11-02 |
WO2018185241A1 (en) | 2018-10-11 |
ES2932831T3 (en) | 2023-01-26 |
EP4219713A2 (en) | 2023-08-02 |
IL268828A (en) | 2019-10-31 |
JP2022173554A (en) | 2022-11-18 |
CN110520531A (en) | 2019-11-29 |
CA3057565A1 (en) | 2018-10-11 |
HUE061247T2 (en) | 2023-06-28 |
DK3607069T3 (en) | 2022-11-21 |
AU2018247925A1 (en) | 2019-10-03 |
SI3607069T1 (en) | 2023-02-28 |
LT3607069T (en) | 2023-01-10 |
US20200095580A1 (en) | 2020-03-26 |
FI3607069T3 (en) | 2023-01-13 |
HRP20221400T1 (en) | 2023-01-06 |
JP2020516312A (en) | 2020-06-11 |
PL3607069T3 (en) | 2023-03-06 |
EP4219713A3 (en) | 2023-08-16 |
US12084656B2 (en) | 2024-09-10 |
AU2018247925B2 (en) | 2024-06-06 |
US11015198B2 (en) | 2021-05-25 |
JP7155239B2 (en) | 2022-10-18 |
EP3607069A1 (en) | 2020-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268828A (en) | Products and compositions | |
IL268970A (en) | Novel compositions and methods | |
IL271275A (en) | Compositions comprising curons and uses thereof | |
HUE065174T2 (en) | Hla-based methods and compositions and uses thereof | |
GB201807325D0 (en) | Compositions and methods | |
SG11201707876YA (en) | Microalgal compositions and uses thereof | |
GB202201859D0 (en) | Novel methods and compositions | |
IL269576A (en) | Products and compositions | |
IL269517A (en) | Products and compositions | |
PT3458509T (en) | Products and uses thereof | |
GB201502002D0 (en) | Uses and compositions | |
GB201710288D0 (en) | Products and methods | |
GB201608762D0 (en) | Compositions and uses thereof | |
ZA202004533B (en) | Skin-brightening compositions and methods | |
PL3568203T3 (en) | Compounds and compositions | |
GB201502026D0 (en) | Uses and compositions | |
GB201501991D0 (en) | Uses and compositions | |
GB201712592D0 (en) | Novel compositions and uses thereof | |
GB201614897D0 (en) | Compositions and uses thereof | |
GB201602409D0 (en) | Compositions and uses thereof | |
PT3607068T (en) | Products and compositions | |
PT3607069T (en) | Products and compositions | |
GB201522814D0 (en) | Compositions and uses thereof | |
GB201511886D0 (en) | Uses and compositions | |
GB201811084D0 (en) | Products and compositions |